The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades.

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...

NEW YORK -- New York City Mayor Eric Adams pleaded innocent Friday to federal bribery charges, rejecting claims that he accepted overseas travel, campaign cash and other perks from foreign interests ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...